KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Operating Expenses (2020 - 2023)

Historic Operating Expenses for AbCellera Biologics (ABCL) over the last 4 years, with Q4 2023 value amounting to $75.2 million.

  • AbCellera Biologics' Operating Expenses rose 2681.76% to $75.2 million in Q4 2023 from the same period last year, while for Sep 2024 it was $75.2 million, marking a year-over-year decrease of 7098.91%. This contributed to the annual value of $343.6 million for FY2024, which is 2483.98% up from last year.
  • As of Q4 2023, AbCellera Biologics' Operating Expenses stood at $75.2 million, which was up 2681.76% from $61.5 million recorded in Q3 2023.
  • AbCellera Biologics' 5-year Operating Expenses high stood at $91.6 million for Q1 2022, and its period low was $6.8 million during Q1 2020.
  • Over the past 4 years, AbCellera Biologics' median Operating Expenses value was $56.0 million (recorded in 2021), while the average stood at $49.5 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first soared by 55890.25% in 2021, then crashed by 1589.53% in 2023.
  • Over the past 4 years, AbCellera Biologics' Operating Expenses (Quarter) stood at $47.1 million in 2020, then increased by 22.59% to $57.8 million in 2021, then increased by 2.67% to $59.3 million in 2022, then grew by 26.82% to $75.2 million in 2023.
  • Its last three reported values are $75.2 million in Q4 2023, $61.5 million for Q3 2023, and $61.4 million during Q2 2023.